Humacyte(NASDAQ) HUMA

Humacyte creates lab-grown blood vessels for people needing urgent vascular repair. Its main product helps patients when natural vein grafts are not available. Hospitals use these vessels for trauma, dialysis, and other surgeries.

What’s in the Humacyte Toolkit?

• Symvess (Bioengineered Vessel): Off-the-shelf blood vessel for urgent vascular repair; 33% of Q2 2025 revenue.
• Contract R&D Services: Research services for medical technology partners; 67% of Q2 2025 revenue.
• Pipeline Products: Vessels in development for dialysis access, artery disease, heart surgery, and cell therapy.
• Pediatric and Specialty Uses: Early-stage products for children’s heart surgery and organ cell delivery.

Growth Moves: Humacyte’s Expansion Playbook

• Launched Symvess in the U.S. in Q1 2025 after FDA approval in December 2024.
• Expanded clinical trials for new uses, including dialysis access and artery disease, from 2023 to 2025.
• Scaled up manufacturing at Durham, NC facility to meet expected demand in 2025.

Why Humacyte Stands Out (Without the Lab Coat)

Humacyte’s vessels are ready-made and do not trigger immune rejection, unlike many alternatives. The company’s technology allows for scalable production of human tissues. Its first FDA-approved product targets a critical need in trauma care.

Five Things You Need to Know

• Revenue was $301,000 in Q2 2025, up from $0 in Q2 2024.
• Operating loss was $29.7 million in Q2 2025, down 0.8% year-over-year.
• Cash and equivalents were $38 million as of June 30, 2025.
• Research and development costs fell 7% year-over-year in Q2 2025.
• Net income for the first half of 2025 was $1.5 million, due to non-cash gains.

Bottom Line

Humacyte has shifted from research to commercial sales with its first FDA-approved product. The company is expanding its pipeline while managing costs and scaling production.